STOCK TITAN

[6-K] Haleon plc Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Haleon plc completed a tranche of its share buyback programme, acquiring 5,214,540 ordinary shares (₣0.01 each) on 17 September 2025. The company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 14,573,545 are held in treasury, leaving 8,937,780,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company's investor website.

Haleon plc ha completato una tranche del proprio programma di riacquisto azioni, acquistando 5.214.540 azioni ordinarie (£0,01 ciascuna) il 17 settembre 2025. L'azienda intende mantenere le azioni acquistate come azioni proprie. Dopo la regolazione, il capitale sociale registrato è di 8.952.353.648 azioni ordinarie, di cui 14.573.545 sono detenute in tesoreria, lasciando 8.937.780.103 azioni ordinarie con diritto di voto. Una ripartizione completa delle singole operazioni è disponibile tramite il link RNS fornito e sul sito degli investitori della società.

Haleon plc completó una tranche de su programa de recompra de acciones, adquiriendo 5.214.540 acciones ordinarias (£0,01 cada una) el 17 de septiembre de 2025. La empresa tiene la intención de mantener las acciones adquiridas como acciones propias. Tras la liquidación, el capital social registrado es de 8.952.353.648 acciones ordinarias, de las que 14.573.545 están en tesorería, quedando 8.937.780.103 acciones ordinarias con derechos de voto. Un desglose completo de las operaciones individuales está disponible a través del enlace RNS proporcionado y en el sitio de inversores de la empresa.

헤일론 plc는 주식매입 프로그램의 한 차례를 완료하고 2025년 9월 17일에 보통주 5,214,540주를 매수했습니다(주당 £0.01). 회사는 매입한 주식을 자사주로 보유할 예정입니다. 결제 후 등록된 자본금은 8,952,353,648주이고 그 중 14,573,545주가 자사주로 보유되어 남는 것은 의결권이 있는 8,937,780,103주입니다. 개별 거래의 전체 내역은 제공된 RNS 링크와 회사의 투자자 웹사이트에서 확인할 수 있습니다.

Haleon plc a terminé une tranche de son programme de rachat d’actions en acquérant 5 214 540 actions ordinaires (0,01 £ chacune) le 17 septembre 2025. La société a l’intention de conserver les actions achetées comme actions propres. Après règlement, le capital social enregistré est de 8 952 353 648 actions ordinaires, dont 14 573 545 sont détenues en trésorerie, laissant 8 937 780 103 actions ordinaires avec droit de vote. Une ventilation complète des transactions individuelles est disponible via le lien RNS fourni et sur le site des investisseurs de la société.

Haleon plc hat eine Tranche seines Aktienrückkaufprogramms abgeschlossen und am 17. September 2025 5.214.540 Stammaktien (£0,01 je Aktie) erworben. Das Unternehmen beabsichtigt, die erworbenen Aktien als Treasury-Aktien zu halten. Nach Abwicklung beträgt das registrierte Aktienkapital 8.952.353.648 Stammaktien, davon 14.573.545 in Treuhandbesitz gehalten, was 8.937.780.103 Stammaktien mit Stimmrechten verbleibt. Eine vollständige Aufschlüsselung der einzelnen Trades ist über den bereitgestellten RNS-Link und auf der Investorenseite des Unternehmens verfügbar.

أكملت شركة Haleon plc دفعة من برنامج إعادة شراء الأسهم الخاص بها، حيث اشترت 5,214,540 سهماً عاديًا (£0.01 لكل سهم) في 17 سبتمبر 2025. تعتزم الشركة الاحتفاظ بالأسهم المشتراة كأسهم خزينة. بعد التسوية، رأس المال المسجل للسهم العادي هو 8,952,353,648 سهما، منها 14,573,545 سهماً في الخزينة، ما يترك 8,937,780,103 سهماً عاديًا ذو حقوق تصويت. يمكن الاطلاع على التفاصيل الكاملة للصفقات الفردية عبر رابط RNS المقدم وعلى موقع الشركة للمستثمرين.

Haleon plc 于2025年9月17日完成了其回购计划的一笔交易,购买5,214,540股普通股(每股0.01英镑)。 公司拟将所购股份作为库藏股持有。结算后,注册股本为8,952,353,648股普通股,其中14,573,545股处于库藏,留下 具有表决权的8,937,780,103股普通股。可通过所提供的RNS链接以及公司投资者网站获取单笔交易的完整明细。

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, routine tranche of a buyback; updates share count and treasury holdings but no earnings or cash detail disclosed.

The announcement documents the purchase of 5,214,540 shares under the second tranche of the previously announced buyback. Management will hold these as treasury shares and provides the updated counts for registered capital, treasury holdings and voting shares, enabling shareholders to assess disclosure thresholds under FCA rules. The filing does not disclose purchase funding, total programme size remaining, or financial impact on cash or EPS.

TL;DR: Corporate action is procedural and compliant, supplying required post-trade share totals for regulatory reporting.

The disclosure complies with Market Abuse Regulation requirements by providing a trade breakdown link and updated share capital figures. By holding shares in treasury, Haleon has preserved flexibility for future use. The filing supplies the precise voting share count investors need for threshold notifications but contains no commentary on board authorization limits or timing for further tranches.

Haleon plc ha completato una tranche del proprio programma di riacquisto azioni, acquistando 5.214.540 azioni ordinarie (£0,01 ciascuna) il 17 settembre 2025. L'azienda intende mantenere le azioni acquistate come azioni proprie. Dopo la regolazione, il capitale sociale registrato è di 8.952.353.648 azioni ordinarie, di cui 14.573.545 sono detenute in tesoreria, lasciando 8.937.780.103 azioni ordinarie con diritto di voto. Una ripartizione completa delle singole operazioni è disponibile tramite il link RNS fornito e sul sito degli investitori della società.

Haleon plc completó una tranche de su programa de recompra de acciones, adquiriendo 5.214.540 acciones ordinarias (£0,01 cada una) el 17 de septiembre de 2025. La empresa tiene la intención de mantener las acciones adquiridas como acciones propias. Tras la liquidación, el capital social registrado es de 8.952.353.648 acciones ordinarias, de las que 14.573.545 están en tesorería, quedando 8.937.780.103 acciones ordinarias con derechos de voto. Un desglose completo de las operaciones individuales está disponible a través del enlace RNS proporcionado y en el sitio de inversores de la empresa.

헤일론 plc는 주식매입 프로그램의 한 차례를 완료하고 2025년 9월 17일에 보통주 5,214,540주를 매수했습니다(주당 £0.01). 회사는 매입한 주식을 자사주로 보유할 예정입니다. 결제 후 등록된 자본금은 8,952,353,648주이고 그 중 14,573,545주가 자사주로 보유되어 남는 것은 의결권이 있는 8,937,780,103주입니다. 개별 거래의 전체 내역은 제공된 RNS 링크와 회사의 투자자 웹사이트에서 확인할 수 있습니다.

Haleon plc a terminé une tranche de son programme de rachat d’actions en acquérant 5 214 540 actions ordinaires (0,01 £ chacune) le 17 septembre 2025. La société a l’intention de conserver les actions achetées comme actions propres. Après règlement, le capital social enregistré est de 8 952 353 648 actions ordinaires, dont 14 573 545 sont détenues en trésorerie, laissant 8 937 780 103 actions ordinaires avec droit de vote. Une ventilation complète des transactions individuelles est disponible via le lien RNS fourni et sur le site des investisseurs de la société.

Haleon plc hat eine Tranche seines Aktienrückkaufprogramms abgeschlossen und am 17. September 2025 5.214.540 Stammaktien (£0,01 je Aktie) erworben. Das Unternehmen beabsichtigt, die erworbenen Aktien als Treasury-Aktien zu halten. Nach Abwicklung beträgt das registrierte Aktienkapital 8.952.353.648 Stammaktien, davon 14.573.545 in Treuhandbesitz gehalten, was 8.937.780.103 Stammaktien mit Stimmrechten verbleibt. Eine vollständige Aufschlüsselung der einzelnen Trades ist über den bereitgestellten RNS-Link und auf der Investorenseite des Unternehmens verfügbar.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F ☐                  
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
18 September 2025- “Transaction in Own Shares”
 
 
99.1
 
 
Haleon plc: Transaction in own shares
 
18 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,214,540 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
  CBOE (UK)/BXE
 CBOE (UK)/CXE
Date of purchase:
17 September 2025
17 September 2025
17 September 2025
Number of Shares purchased:
3,315,000
1,899,540
-
Highest price paid per Share (p):
343.9000
343.0000
-
Lowest price paid per Share (p):
340.8000
340.8000
-
Volume weighted average price paid per Share (p):
342.6323
342.5237
-
 
The Company intends to hold the purchased shares as treasury shares.
 
Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 14,573,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,937,780,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/7745Z_1-2025-9-17.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
 
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: September 18, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary
HALEON PLC

OTC:HLNCF

HLNCF Rankings

HLNCF Latest SEC Filings

HLNCF Stock Data

8.93B